{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T04:48:51Z","timestamp":1763786931428,"version":"3.45.0"},"reference-count":30,"publisher":"Japan Neurosurgical Society","issue":"0","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.2176\/jns-nmc.2025-0205","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T22:09:21Z","timestamp":1763676561000},"page":"505-509","source":"Crossref","is-referenced-by-count":0,"title":["Successful Clazosentan Therapy for Subarachnoid Hemorrhage after Coil Embolization of Ruptured Posterior Cerebral Artery Aneurysm in a Patient with Moyamoya Disease: A Case Report"],"prefix":"10.2176","volume":"12","author":[{"given":"Haruto","family":"UCHINO","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Hokkaido University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"SUGIYAMA","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Hokkaido University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"HOKARI","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Teine Keijinkai Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"YAMAGUCHI","sequence":"additional","affiliation":[{"name":"Department of Cerebrovascular Medicine, Teine Keijinkai Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiya","family":"OSANAI","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Hokkaido University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"FUJIMURA","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Hokkaido University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"971","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1) Suzuki J, Takaku A. Cerebrovascular &quot;moyamoya&quot; disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969;20 (3):288-99. doi: 10.1001\/archneur.1969.00480090076012","DOI":"10.1001\/archneur.1969.00480090076012"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2) Furtado SV, Medress ZA, Teo M, et al. Pathogenesis of aneurysms on major vessels in Moyamoya disease and management outcome. J Clin Neurosci. 2019;61:219-24. doi: 10.1016\/j.jocn.2018.09.023","DOI":"10.1016\/j.jocn.2018.09.023"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3) Kawaguchi S, Sakaki T, Morimoto T, et al. Characteristics of intracranial aneurysms associated with Moyamoya disease. A review of 111 cases. Acta Neurochir (Wien). 1996;138 (11):1287-94. doi: 10.1007\/BF01411057","DOI":"10.1007\/BF01411057"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4) Larson AS, Rinaldo L, Brinjikji W, et al. Location-based treatment of intracranial aneurysms in Moyamoya disease: a systematic review and descriptive analysis. Neurosurg Rev. 2021;44 (2):1127-39. doi: 10.1007\/s10143-020-01307-1","DOI":"10.1007\/s10143-020-01307-1"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5) Ni W, Jiang H, Xu B, et al. Treatment of aneurysms in patients with Moyamoya disease: a 10-year single-center experience. J Neurosurg. 2018;128 (6):1813-22. doi: 10.3171\/2017.3.JNS162290","DOI":"10.3171\/2017.3.JNS162290"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6) Fujimura M, Joo JY, Kim JS, et al. Preventive effect of clazosentan against cerebral vasospasm after clipping surgery for aneurysmal subarachnoid hemorrhage in Japanese and Korean patients. Cerebrovasc Dis. 2017;44 (1-2):59-67. doi: 10.1159\/000475824","DOI":"10.1159\/000475824"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Endo H, Hagihara Y, Kimura N, et al. Effects of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients. J Neurosurg. 2022;137 (6):1707-17. doi: 10.3171\/2022.2.JNS212914","DOI":"10.3171\/2022.2.JNS212914"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8) Pontes JPM, Santos MDC, Gibram FC, et al. Efficacy and safety of clazosentan after aneurysmal subarachnoid hemorrhage: an updated meta-analysis. Neurosurgery. 2023;93 (6):1208-19. doi: 10.1227\/neu.0000000000002601","DOI":"10.1227\/neu.0000000000002601"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9) Raja S, Raja A, Shuja MH, et al. Clazosentan&apos;s dual edge in managing vasospasm following aneurysmal subarachnoid hemorrhage: an updated systematic review, meta-analysis, and meta-regression of clinical outcomes and safety profiles. Neurosurg Rev. 2025;48 (1):20. doi: 10.1007\/s10143-024-03173-7","DOI":"10.1007\/s10143-024-03173-7"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10) Sugiyama T, Hokari M, Shimbo D, et al. Clinical factors associated with delayed ischemic and non-ischemic adverse events in clazosentan therapy after aneurysmal subarachnoid hemorrhage: early insights from a multicenter prospective registry. Neurosurg Rev. 2025;48 (1):482. doi: 10.1007\/s10143-025-03646-3","DOI":"10.1007\/s10143-025-03646-3"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11) Daou BJ, Koduri S, Thompson BG, et al. Clinical and experimental aspects of aneurysmal subarachnoid hemorrhage. CNS Neurosci Ther. 2019;25 (10):1096-112. doi: 10.1111\/cns.13222","DOI":"10.1111\/cns.13222"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332 (6163):411-5. doi: 10.1038\/332411a0","DOI":"10.1038\/332411a0"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Mayer SA, Bruder N, Citerio G, et al. REACT: a randomized trial to assess the efficacy and safety of clazosentan for preventing clinical deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2025;142 (1):98-109. doi: 10.3171\/2024.4.JNS232191","DOI":"10.3171\/2024.4.JNS232191"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Muraoka S, Izumi T, Nishida K, et al. RECOVER study: a multicenter retrospective cohort study and comparison of the efficacy and safety of clazosentan and fasudil in patients with aneurysmal subarachnoid hemorrhage. J Neurol Surg. 2025;1-10. doi: 10.3171\/2025.1.JNS242509","DOI":"10.3171\/2025.1.JNS242509"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15) Sakata H, Kanoke A, Uchida H, et al. Prophylactic management of cerebral vasospasm with clazosentan in real clinical practice: a single-center retrospective cohort study. Front Neurol. 2024;15:1413632. doi: 10.3389\/fneur.2024.1413632","DOI":"10.3389\/fneur.2024.1413632"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16) Oishi H, Kato T, Hasegawa T, et al. Clazosentan-induced reversible focal brain edema in basal ganglia following aneurysmal subarachnoid hemorrhage treatment: illustrative case. J Neurosurg Case Lessons. 2024;8 (20):CASE24567. doi: 10.3171\/CASE24567","DOI":"10.3171\/CASE24567"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17) Ito M, Uchino H, Fujimura M. Intraoperative Cortical Indocyanine Green Extravasation as a Predictor of Cerebral hyperperfusion following Direct revascularization for Moyamoya disease- impact of Prolonged Observations of ICG videoangiography. Cerebrovasc Dis. 2025;1-15. doi: 10.1159\/000545333","DOI":"10.1159\/000545333"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18) Uchino H, Ito M, Kurisu K, et al. Association between intracranial vascular vulnerability and indirect revascularization development in Moyamoya disease. Neurosurg Rev. 2025;48 (1):387. doi: 10.1007\/s10143-025-03544-8","DOI":"10.1007\/s10143-025-03544-8"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19) Uchino H, Ito M, Tokairin K, et al. Association of RNF213 polymorphism and cortical hyperintensity sign on fluid-attenuated inversion recovery images after revascularization surgery for Moyamoya disease: possible involvement of intrinsic vascular vulnerability. Neurosurg Rev. 2023;46 (1):119. doi: 10.1007\/s10143-023-02030-3","DOI":"10.1007\/s10143-023-02030-3"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20) Fujimura M, Watanabe M, Narisawa A, et al. Increased expression of serum matrix metalloproteinase-9 in patients with Moyamoya disease. Surg Neurol. 2009;72 (5):476-80; discussion 480. doi: 10.1016\/j.surneu.2008.10.009","DOI":"10.1016\/j.surneu.2008.10.009"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21) Roy V, Ross JP, P\u00e9pin R, et al. Moyamoya disease susceptibility gene RNF213 regulates endothelial barrier function. Stroke. 2022;53 (4):1263-75. doi: 10.1161\/STROKEAHA.120.032691","DOI":"10.1161\/STROKEAHA.120.032691"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22) Narducci A, Yasuyuki K, Onken J, et al. In vivo demonstration of blood-brain barrier impairment in Moyamoya disease. Acta Neurochir (Wien). 2019;161 (2):371-8. doi: 10.1007\/s00701-019-03811-w","DOI":"10.1007\/s00701-019-03811-w"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23) Chen Y, Dai D, Fang Y, et al. Endovascular treatment of ruptured large or wide-neck basilar tip aneurysms associated with Moyamoya disease using the stent-assisted coil technique. J Stroke Cerebrovasc Dis. 2015;24 (10):2229-35. doi: 10.1016\/j.jstrokecerebrovasdis.2015.05.024","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.05.024"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24) Wan M, Han C, Xian P, et al. Moyamoya disease presenting with subarachnoid hemorrhage: clinical features and neuroimaging of a case series. Br J Neurosurg. 2015;29 (6):804-10. doi: 10.3109\/02688697.2015.1071327","DOI":"10.3109\/02688697.2015.1071327"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25) Nakai Y, Hyodo A, Yanaka K, et al. Fatal cerebral infarction after intraventricular hemorrhage in a pregnant patient with Moyamoya disease. J Clin Neurosci. 2002;9 (4):456-8. doi: 10.1054\/jocn.2001.0970","DOI":"10.1054\/jocn.2001.0970"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26) Matsuoka G, Kubota Y, Okada Y. Delayed cerebral ischemia associated with reversible cerebral vasoconstriction in a patient with Moyamoya disease with intraventricular hemorrhage: case report. Neuroradiol J. 2015;28 (3):322-4. doi: 10.1177\/1971400915592553","DOI":"10.1177\/1971400915592553"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27) Hikino K, Koyama S, Ito K, et al. RNF213 variants, vasospastic angina, and risk of fatal myocardial infarction. JAMA Cardiol. 2024;9 (8):723-31. doi: 10.1001\/jamacardio.2024.1483","DOI":"10.1001\/jamacardio.2024.1483"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28) Hitomi T, Habu T, Kobayashi H, et al. Downregulation of Securin by the variant RNF213 R4810K (rs112735431, G&gt;A) reduces angiogenic activity of induced pluripotent stem cell-derived vascular endothelial cells from moyamoya patients. Biochem Biophys Res Commun. 2013;438 (1):13-9. doi: 10.1016\/j.bbrc.2013.07.004","DOI":"10.1016\/j.bbrc.2013.07.004"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29) Hamauchi S, Shichinohe H, Uchino H, et al. Cellular functions and gene and protein expression profiles in endothelial cells derived from Moyamoya disease-specific iPS cells. PLOS One. 2016;11 (9):e0163561. doi: 10.1371\/journal.pone.0163561","DOI":"10.1371\/journal.pone.0163561"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30) Tokairin K, Hamauchi S, Ito M, et al. Vascular smooth muscle cell derived from IPS cell of Moyamoya disease - comparative characterization with endothelial cell transcriptome. J Stroke Cerebrovasc Dis. 2020;29 (12):105305. doi: 10.1016\/j.jstrokecerebrovasdis.2020.105305","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105305"}],"container-title":["NMC Case Report Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmccrj\/12\/0\/12_2025-0205\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T04:45:36Z","timestamp":1763786736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmccrj\/12\/0\/12_2025-0205\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":30,"journal-issue":{"issue":"0","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2176\/jns-nmc.2025-0205","relation":{},"ISSN":["2188-4226"],"issn-type":[{"type":"electronic","value":"2188-4226"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"article-number":"2025-0205"}}